News for TetraLogic Pharmaceuticals Corporation (TLOG)

Read TetraLogic Pharmaceuticals (OTCMKTS:TLOG) Stock Crosses Below 200-Day Moving Average of $0.01 at ETF Daily News

Read Ocuphire Pharma (NASDAQ:OCUP) & TetraLogic Pharmaceuticals (OTCMKTS:TLOG) Head to Head Review at ETF Daily News

Read TetraLogic Pharmaceuticals (OTCMKTS:TLOG) versus BeiGene (NASDAQ:BGNE) Head to Head Survey at ETF Daily News

Phase II TACTI-002 is Immutep's Phase II study evaluating the combination of efti with KEYTRUDA® in up to 183 patients with non-small cell lung cancer in 1st and 2nd line ... | September 1, 2021

HUDDINGE, Sweden, Aug. 19, 2021 /PRNewswire/ -- April – JuneFinancial summary for the quarterNet turnover amounted to SEK 0.9 (4.0) million. The l...

/PRNewswire/ -- April – June Financial summary for the quarter Net turnover amounted to SEK 0.9 (4.0) million. The loss before interest, tax, depreciation and...

MEDIVIR AB - INTERIM REPORT JANUARY - JUNE 2021 Positive study results for MIV-818 and remetinostat. Design... | August 19, 2021

Medivir AB (Nasdaq Stockholm: MVIR) announced today that Medivir AB ("Medivir" or "the Company") together with the originators of remetinostat, and TetraLogic Pharmaceuticals Corporation and The Leukemia & Lymphoma Society ("the Stakeholders") have restructured and streamlined the financial obligations for remetinostat, a topical histone deacetylase (HDAC) inhibitor, for the treatment of cutaneous T-cell lymphoma (CTCL) and potentially other types of skin cancers. The purpose of the new agreemen